	US 12,251,582 B2
	Pulmonary hypertension treatment
Or Shabtay, Kibbutz Farod (IL); and Dalit Shav, Glen Rock, NJ (US)
Assigned to Sonivie Ltd., Rosh HaAyin (IL)
Filed by Sonivie Ltd., Rosh HaAyin (IL)
Filed on Apr. 13, 2022, as Appl. No. 17/719,412.
Application 17/719,412 is a continuation of application No. 16/494,321, granted, now 11,318,331, previously published as PCT/IL2018/050321, filed on Mar. 20, 2018.
Claims priority of provisional application 62/473,545, filed on Mar. 20, 2017.
Claims priority of provisional application 62/473,512, filed on Mar. 20, 2017.
Claims priority of provisional application 62/473,532, filed on Mar. 20, 2017.
Prior Publication US 2022/0241617 A1, Aug. 4, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 7/00 (2006.01); A61B 17/3203 (2006.01); A61B 18/00 (2006.01); A61B 18/02 (2006.01); A61B 18/06 (2006.01); A61B 18/08 (2006.01); A61B 18/14 (2006.01); A61B 18/24 (2006.01); A61K 31/191 (2006.01); A61K 31/343 (2006.01); A61K 31/4965 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/53 (2006.01); A61N 2/02 (2006.01); A61N 2/06 (2006.01); A61N 5/10 (2006.01); A61N 7/02 (2006.01); A61B 5/055 (2006.01); A61B 6/03 (2006.01); A61B 6/50 (2024.01); A61B 17/00 (2006.01); A61B 18/12 (2006.01); A61B 18/18 (2006.01)

CPC A61N 7/00 (2013.01) [A61B 18/00 (2013.01); A61B 18/0206 (2013.01); A61B 18/082 (2013.01); A61B 18/1492 (2013.01); A61B 18/24 (2013.01); A61K 31/191 (2013.01); A61K 31/343 (2013.01); A61K 31/4965 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/53 (2013.01); A61N 2/06 (2013.01); A61N 5/1002 (2013.01); A61N 7/022 (2013.01); A61B 5/055 (2013.01); A61B 6/032 (2013.01); A61B 6/504 (2013.01); A61B 2017/00292 (2013.01); A61B 2018/00369 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/0212 (2013.01); A61B 2018/1253 (2013.01); A61B 2018/126 (2013.01); A61B 2018/1807 (2013.01); A61B 2018/1861 (2013.01); A61N 2007/003 (2013.01); A61N 2007/0043 (2013.01); A61N 2007/0078 (2013.01)]

40 Claims

1. A method of treating pulmonary arterial hypertension in a subject in need thereof, the method comprising:

a) determining a responsiveness of the subject to at least one therapeutically active agent usable in treating pulmonary arterial hypertension; and

b) effecting pulmonary artery denervation in a subject which has been determined according to (a) as being responsive to said at least one therapeutically active agent,

thereby treating the pulmonary arterial hypertension.